Cue Biopharma (CUE) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• Cue Biopharma is expected to report Q3 2026 results on November 11. Analysts forecast a loss of $2.24 per share and revenue of $1.03 million; the earnings call is scheduled for November 13.
• In its previous quarter, the company reported a $24.14-per-share loss, missing the $1.69 loss consensus, while revenue of $7.88 million exceeded expectations of $3.00 million.
• Analyst views are mixed, with an average rating of Hold and a consensus price target of $83.00. Shares opened at $20.86 in the article.

Cue Biopharma (NASDAQ:CUE - Get Free Report) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($2.2433) per share and revenue of $1.03 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The business had revenue of $7.88 million for the quarter, compared to analysts' expectations of $3.00 million. On average, analysts expect Cue Biopharma to post ($21.79) EPS for the current fiscal year and ($8.70) EPS for the next fiscal year.

Cue Biopharma Trading Up 7.4%

Shares of NASDAQ CUE opened at $20.86 on Wednesday. The business's 50 day moving average price is $25.39 and its 200-day moving average price is $118.82. Cue Biopharma has a fifty-two week low of $4.97 and a fifty-two week high of $45.50.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. B. Riley Financial began coverage on Cue Biopharma in a report on Friday, September 18th. They set a "buy" rating and a $83.00 price objective for the company. Weiss Ratings lowered Cue Biopharma from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 27th. Wall Street Zen lowered Cue Biopharma from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 26th. Finally, Zacks Research upgraded Cue Biopharma to a "hold" rating in a research report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $83.00.

Insider Buying and Selling at Cue Biopharma

In other news, VP Michael Vincent Meluzio sold 5,628 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the sale, the vice president owned 48,961 shares of the company's stock, valued at approximately $1,473,236.49. This represents a 10.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 8,829 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61. Following the transaction, the insider owned 118,545 shares in the company, valued at approximately $3,567,019.05. This represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 86,790 shares of company stock valued at $2,430,815. Company insiders own 14.56% of the company's stock.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company's approach is designed to selectively activate a patient's own T cells against disease-associated antigens while minimizing broad immune-system activation.

Cue Biopharma's product candidates are based on its Immuno-STAT (Selective Targeting and Alteration of T cells) platform, which uses biologic molecules intended to engage specific T-cell receptors and deliver immune-modulating signals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.